Overview
GHS-R1a agonist, activates pituitary somatotrophs and hypothalamic GHRH neurons.
Proposed mechanism
Synthetic hexapeptide GHS that binds ghrelin receptors, stimulating GH release with potency between GHRP-6 and hexarelin.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
GHRP-2 dose response
· DOI:10.1210/jcem.83.6.4870 · 1998
- [2]
GHS comparative potency
· DOI:10.1016/S0083-6729(08)60970-X · 2003
- [3]
GHRP-2 dose response (1998)
· · 0
- [4]
GHS comparative potency (2003)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.